These results suggested that a loss of EP300 expression may skew CD4+ T cells towards a more effector-like Th1 and/or Th17 phenotype that is conducive to more robust BsAb-mediated target tumor cell killing, but that fails to benefit long-term T cell proliferation. The gene discussed is EP300; the disease is neoplasm.